First Horizon Advisors, Inc. Spring Works Therapeutics, Inc. Transaction History

First Horizon Advisors, Inc.

$3.58 Billion
Q3 2024

A detailed history of First Horizon Advisors, Inc. transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, First Horizon Advisors, Inc. holds 1,183 shares of SWTX stock, worth $42,102. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,183

Previous 1,183 -0.0%

Holding current value

$42,102

Previous $44,000 15.91%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 19, 2024	BUY	$36.06 - $47.62 $13,810 - $18,238	383 Added 47.88%	1,183 $44,000
Q1 2024 Apr 26, 2024	SELL	$36.5 - $52.5 $2,445 - $3,517	-67 Reduced 7.73%	800 $39,000
Q4 2023 Feb 06, 2024	SELL	$18.94 - $37.24 $435 - $856	-23 Reduced 2.58%	867 $31,000
Q3 2023 Oct 27, 2023	BUY	$23.12 - $31.38 $1,017 - $1,380	44 Added 5.2%	890 $20,000
Q1 2023 May 15, 2023	BUY	$24.97 - $34.05 $49 - $68	2 Added 0.24%	846 $21,000
Q4 2022 Feb 10, 2023	SELL	$21.73 - $28.72 $1,673 - $2,211	-77 Reduced 8.36%	844 $21,000
Q3 2022 Nov 09, 2022	BUY	$24.1 - $39.66 $3,904 - $6,424	162 Added 21.34%	921 $26,000
Q2 2022 Aug 02, 2022	BUY	$18.36 - $60.07 $13,788 - $45,112	751 Added 9387.5%	759 $18,000
Q1 2022 May 10, 2022	SELL	$48.97 - $65.46 $21,301 - $28,475	-435 Reduced 98.19%	8 $0
Q4 2021 Feb 09, 2022	BUY	$53.3 - $75.84 $10,979 - $15,623	206 Added 86.92%	443 $27,000
Q3 2021 Nov 15, 2021	BUY	$62.66 - $88.26 $8,396 - $11,826	134 Added 130.1%	237 $15,000
Q3 2021 Nov 09, 2021	BUY	$62.66 - $88.26 $6,453 - $9,090	103 New	103 $6,000

Others Institutions Holding SWTX

# of Institutions

237

Shares Held

68.9M

Call Options Held

144K

Put Options Held

257K

View Full List

About SpringWorks Therapeutics, Inc.

Ticker SWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,401,100
Market Cap $2.22B
Description
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...

More about SWTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of First Horizon Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Horizon Advisors, Inc. with notifications on news.

Account

First Horizon Advisors, Inc. Spring Works Therapeutics, Inc. Transaction History